
  
    
      
        Background_NNP
        Gene_NNP transfer_VB into_IN developing_VBG and_CC mature_VBP primary_JJ T_NN cells_NNS
        has_VBZ been_VBN limited_VBN by_IN the_DT lack_NN of_IN efficient_JJ techniques_NNS for_IN ex_FW
        vivo_NN or_CC in_IN vivo_NN transfection_NN or_CC transduction_NN ._. The_DT
        adaptation_NN of_IN retroviral_NN vectors_NNS for_IN gene_NN delivery_NN into_IN
        lymphocytes_NNS has_VBZ gained_VBN favor_NN recently_RB [_NN 1_CD 2_CD ]_NN ,_, but_CC has_VBZ
        several_JJ features_NNS that_WDT limit_NN its_PRP$ use_NN ._. First_LS ,_, retroviral_NN gene_NN
        transduction_NN requires_VBZ cell_NN cycle_NN progression_NN of_IN the_DT
        cellular_JJ host_NN to_TO permit_VB viral_JJ genome_NN integration_NN ,_, limiting_VBG
        studies_NNS of_IN regulatory_JJ genes_NNS that_WDT are_VBP operative_JJ early_RB in_IN T_NN
        cell_NN activation_NN or_CC differentiation_NN ._. Second_JJ ,_, because_IN the_DT
        integration_NN site_NN of_IN the_DT viral_JJ genome_NN is_VBZ variable_JJ ,_, there_EX can_MD
        be_VB local_JJ ,_, host_NN chromatin_NN effects_NNS on_IN exogenous_JJ gene_NN
        expression_NN and_CC unpredictable_JJ silencing_VBG of_IN viral_JJ integrants_NNS ._.
        Third_NNP ,_, efficiencies_NNS of_IN transduction_NN with_IN retroviral_NN vectors_NNS
        are_VBP often_RB limiting_VBG ._. Finally_RB ,_, the_DT retroviral_NN genome_NN is_VBZ
        small_JJ ,_, limiting_VBG the_DT size_NN of_IN exogenous_JJ genes_NNS that_WDT can_MD be_VB
        packaged_VBN ._.
        Replication-defective_NNP adenoviral_NN vectors_NNS offer_VBP several_JJ
        advantages_NNS that_WDT make_VBP them_PRP attractive_JJ for_IN gene_NN delivery_NN [_NN 3_CD
        4_CD 5_CD 6_CD ]_NN ._. Adenoviral_NNP vectors_NNS are_VBP able_JJ to_TO transduce_NN
        proliferating_VBG or_CC quiescent_JJ cells_NNS ;_: they_PRP can_MD accommodate_VB
        dual_JJ ,_, large_JJ insert_NN sizes_NNS and_CC can_MD deliver_VB additional_JJ genes_NNS
        by_IN superinfection_NN ;_: and_CC stable_JJ ,_, high-titer_JJ viral_JJ stocks_NNS are_VBP
        easily_RB generated_VBN [_NN 7_CD ]_NN ._. Further_RB ,_, since_IN the_DT adenoviral_NN
        genome_NN is_VBZ maintained_VBN extra-chromosomally_JJ ,_, insertion_NN
        site-dependent_JJ effects_NNS of_IN the_DT host_NN genome_NN are_VBP minimized_VBN ,_,
        and_CC exogenous_JJ genes_NNS can_MD be_VB reliably_RB expressed_VBN at_IN high_JJ
        levels_NNS ._. Unfortunately_RB ,_, naive_JJ lymphocytes_NNS are_VBP not_RB
        susceptible_JJ to_TO infection_NN with_IN adenoviruses_NNS due_JJ to_TO lack_NN of_IN
        detectable_JJ expression_NN of_IN a_DT viral_JJ receptor_NN ,_, such_JJ as_IN the_DT
        coxsackie_NN /_NN adenovirus_JJ receptor_NN (_( CAR_NNP )_) ,_, which_WDT is_VBZ required_VBN for_IN
        efficient_JJ viral_JJ attachment_NN [_NN 8_CD 9_CD 10_CD ]_NN ._. The_DT CAR_NNP protein_NN
        contains_VBZ two_CD extra-cellular_JJ immunoglobulin-like_JJ (_( Ig_NNP )_)
        domains_NNS ,_, the_DT first_JJ of_IN which_WDT appears_VBZ sufficient_JJ for_IN binding_VBG
        to_TO the_DT adenoviral_NN fiber_NN knob_NN protein_NN [_NN 11_CD 12_CD ]_NN ._. Expression_NNP
        of_IN either_DT human_NN or_CC murine_NN CAR_NNP in_IN various_JJ cell_NN lines_NNS has_VBZ
        been_VBN shown_VBN to_TO facilitate_VB gene_NN transfer_NN by_IN recombinant_JJ human_JJ
        adenoviruses_NNS [_NN 8_CD 9_CD 10_CD 13_CD ]_NN ._. Stable_NNP transfection_NN of_IN
        transformed_VBN murine_NN B_NNP and_CC T_NN cells_NNS lines_NNS with_IN human_JJ CAR_NNP
        (_( hCAR_NN )_) lacking_VBG its_PRP$ cytoplasmic_JJ domain_NN rendered_VBD them_PRP
        susceptible_JJ to_TO adenoviral_NN transfection_NN ,_, establishing_VBG that_IN
        lymphoid_NN cells_NNS can_MD be_VB permissive_JJ hosts_NNS for_IN adenoviral_NN
        transduction_NN and_CC demonstrating_VBG that_IN the_DT cytoplasmic_JJ domain_NN
        of_IN CAR_NNP is_VBZ not_RB required_VBN for_IN viral_JJ entry_NN [_NN 13_CD ]_NN ._. More_RBR
        recently_RB ,_, mice_NNS transgenic_JJ for_IN full_JJ length_NN [_NN 14_CD ]_NN or_CC
        truncated_JJ hCAR_NN [_NN 15_CD ]_NN have_VBP been_VBN described_VBN in_IN which_WDT
        adenoviral_NN transduction_NN of_IN primary_JJ lymphocytes_NNS has_VBZ been_VBN
        demonstrated_VBN ._.
        We_PRP describe_VBP here_RB three_CD new_JJ transgenic_JJ (_( Tg_NNP )_) mouse_NN lines_NNS
        in_IN which_WDT expression_NN of_IN human_JJ CAR_NNP with_IN a_DT truncated_JJ
        cytoplasmic_JJ domain_NN (_( hCARΔcyt_NN )_) is_VBZ limited_VBN to_TO thymocytes_NNS and_CC
        lymphocytes_NNS under_IN direction_NN of_IN a_DT human_JJ CD_NNP 2_CD mini-gene_JJ [_NN 16_CD ]_NN
        ._. The_DT three_CD lines_NNS are_VBP similar_JJ in_IN having_VBG transgene_NN
        expression_NN restricted_VBN to_TO the_DT lymphoid_NN lineage_NN ,_, but_CC differ_VB
        in_IN the_DT pattern_NN of_IN hCARΔcyt_NN expression_NN profiles_NNS within_IN
        lymphoid_NN populations_NNS ._. In_IN each_DT transgenic_JJ line_NN ,_, expression_NN
        of_IN the_DT hCARΔcyt_NN transgene_NN imparted_JJ susceptibility_NN to_TO
        efficient_JJ adenoviral_NN transduction_NN that_WDT was_VBD independent_JJ of_IN
        cellular_JJ activation_NN ._. By_IN crossing_VBG the_DT hCARΔcyt_NN ._. CD_NNP 2_CD Tg_NNP mice_NNS
        with_IN DO_NNP 11_CD ._. 10_CD TCR_NNP Tg_NNP mice_NNS ,_, we_PRP have_VBP generated_VBN an_DT
        antigen-specific_JJ model_NN with_IN which_WDT to_TO study_VB the_DT effects_NNS of_IN
        adenovirally_RB delivered_VBN genes_NNS on_IN T_NN cell_NN activation_NN and_CC
        differentiation_NN ._. Transduction_NNP of_IN hCARΔcyt-positive_JJ naïve_NN ,_,
        Th_NNP 1_CD or_CC Th_NNP 2_CD DO_NNP 11_CD ._. 10_CD T_NN cells_NNS with_IN a_DT recombinant_JJ adenoviral_NN
        vector_NN resulted_VBD in_IN high-level_JJ reporter_NN gene_NN expression_NN
        without_IN detectable_JJ activation_NN of_IN transduced_JJ cells_NNS or_CC
        deleterious_JJ effect_NN on_IN their_PRP$ antigenic_JJ responses_NNS ._.
      
      
        Results_NNS
        
          hCARΔcyt_NN ._. CD_NNP 2_CD transgenic_JJ mice_NNS :_: characterization_NN of_IN
          distinct_JJ hCAR_NN expression_NN profiles_NNS in_IN three_CD different_JJ
          founder_NN lines_NNS
          To_TO develop_VB a_DT transgenic_JJ model_NN with_IN high-level_JJ
          expression_NN of_IN hCAR_NN on_IN murine_NN T_NN cells_NNS ,_, a_DT transgene_NN was_VBD
          constructed_VBN based_VBN on_IN a_DT human_JJ CD_NNP 2_CD mini-gene_JJ described_VBD
          previously_RB [_NN 16_CD ]_NN (_( Fig_NNP ._. 1_LS A_DT )_) ._. This_DT mini-gene_JJ includes_VBZ the_DT
          5_CD '_POS promoter_NN region_NN of_IN the_DT hCD_NN 2_CD gene_NN as_RB well_RB as_IN the_DT hCD_NN 2_CD
          LCR_NNP ,_, which_WDT is_VBZ reported_VBN to_TO direct_VB transgene_NN expression_NN to_TO
          T_NN cells_NNS in_IN a_DT position-independent_JJ ,_, copy_NN number-dependent_JJ
          manner_NN [_NN 17_CD 18_CD ]_NN ._. Since_IN the_DT function_NN of_IN CAR_NNP is_VBZ
          undefined_JJ ,_, and_CC deletion_NN of_IN the_DT cytoplasmic_JJ tail_NN of_IN hCAR_NN
          does_VBZ not_RB adversely_RB affect_VB adenoviral_NN transduction_NN [_NN 13_CD 19_CD
          ]_NN ,_, a_DT cDNA_NN encoding_VBG a_DT cytoplasmic_JJ tail-truncated_JJ variant_NN
          of_IN hCAR_NN (_( hCARΔcyt_NN )_) was_VBD generated_VBN and_CC inserted_VBN into_IN the_DT
          CD_NNP 2_CD mini-gene_JJ to_TO eliminate_VB any_DT potential_JJ signaling_VBG
          capacity_NN of_IN hCAR_NN ._. Of_IN eight_CD founder_NN mice_NNS bearing_VBG an_DT intact_JJ
          transgene_NN ,_, all_DT demonstrated_VBN lymphoid_NN lineage-specific_JJ
          expression_NN of_IN hCARΔcyt_NN ,_, with_IN three_CD distinct_JJ expression_NN
          profiles_NNS represented_VBN by_IN founder_NN lines_NNS 6_CD ,_, 13_CD ,_, and_CC 18_CD
          (_( Figure_NN 1_CD Band_NNP data_NNS not_RB shown_VBN )_) ._. To_TO develop_VB an_DT
          antigen-specific_JJ T_NN cell_NN system_NN with_IN which_WDT to_TO deliver_VB
          genes_NNS of_IN interest_NN ,_, each_DT of_IN these_DT lines_NNS was_VBD then_RB crossed_VBN
          with_IN DO_NNP 11_CD ._. 10_CD TCR_NNP Tg_NNP mice_NNS [_NN 20_CD ]_NN to_TO generate_VB the_DT
          DO_NNP 11_CD ._. hCARΔcyt_NN double_JJ transgenic_JJ lines_NNS shown_VBN (_( Figure_NN
          1_CD B_NNP &_CC 1_CD C_NNP )_) ._.
          Lymph_NNP node_NN cells_NNS were_VBD isolated_VBN from_IN mice_NNS in_IN
          DO_NNP 11_CD ._. hCARΔcyt_NN lines_NNS 6_CD ,_, 13_CD and_CC 18_CD ,_, stained_JJ with_IN antibodies_NNS
          to_TO CD_NNP 4_CD ,_, CD_NNP 8_CD ,_, CD_NNP 19_CD and_CC RmcB_NNP (_( anti-h_JJ CAR_NNP )_) and_CC analyzed_VBN by_IN
          flow_NN cytometry_NN (_( Fig_NNP ._. 1_LS B_NNP )_) ._. All_DT of_IN the_DT CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN
          cells_NNS from_IN line_NN 6_CD and_CC 18_CD expressed_VBD high_JJ levels_NNS of_IN the_DT
          hCARΔcyt_NN transgene_NN ,_, while_IN CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS from_IN line_NN
          13_CD had_VBD a_DT bimodal_NN pattern_NN of_IN expression_NN ,_, with_IN
          approximately_RB 35_CD %_NN of_IN both_DT CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN negative_JJ for_IN
          hCARΔcyt_NN ._. While_IN both_DT lines_NNS 13_CD and_CC 18_CD had_VBD negligible_JJ
          expression_NN in_IN the_DT B_NNP cell_NN compartment_NN ,_, the_DT vast_JJ majority_NN
          of_IN B_NNP cells_NNS from_IN line_NN 6_CD expressed_VBD the_DT hCARΔcyt_NN transgene_NN ,_,
          although_IN at_IN a_DT lower_JJR level_NN than_IN the_DT T_NN cells_NNS (_( mean_VB
          fluorescence_NN intensity_NN (_( MFI_NNP )_) :_: CD_NNP 19_CD +_NN B_NNP cells_NNS ,_, 64_CD ;_: CD_NNP 4_CD +_NN T_NN
          cells_NNS ,_, 193_CD )_) ._. hCARΔcyt_NN was_VBD not_RB detected_VBN in_IN non-lymphoid_JJ
          tissues_NNS nor_CC on_IN lymphocytes_NNS from_IN non-transgenic_JJ littermate_NN
          controls_NNS (_( data_NNS not_RB shown_VBN )_) ._.
          To_TO determine_VB at_IN what_WP developmental_NN stage_NN the_DT hCARΔcyt_NN
          transgene_NN is_VBZ expressed_VBN in_IN T_NN cells_NNS ,_, thymocytes_NNS were_VBD
          isolated_VBN from_IN 4_CD -_: week-old_JJ mice_NNS and_CC the_DT expression_NN of_IN
          hCARΔcyt_NN relative_JJ to_TO the_DT expression_NN of_IN CD_NNP 4_CD and_CC CD_NNP 8_CD was_VBD
          evaluated_VBN (_( Fig_NNP ._. 1_LS C_NNP )_) ._. Consistent_NNP with_IN the_DT expression_NN of_IN
          hCARΔcyt_NN on_IN mature_VBP CD_NNP 4_CD +_NN and_CC CD_NNP 8_CD +_NN T_NN cells_NNS from_IN lines_NNS 6_CD and_CC
          18_CD ,_, all_DT of_IN the_DT thymocytes_NNS in_IN the_DT CD_NNP 4_CD +_NN CD_NNP 8_CD +_NN double_JJ
          positive_JJ (_( DP_NNP )_) and_CC CD_NNP 4_CD +_NN or_CC CD_NNP 8_CD +_NN single_JJ positive_JJ (_( SP_NNP )_)
          fractions_NNS were_VBD positive_JJ for_IN hCARΔcyt_NN ._. In_IN line_NN 13_CD ,_,
          approximately_RB 68_CD %_NN of_IN the_DT DP_NNP and_CC SP_NNP cells_NNS expressed_VBD
          hCARΔcyt_NN ,_, consistent_JJ with_IN the_DT expression_NN of_IN hCARΔcyt_NN on_IN T_NN
          cells_NNS in_IN the_DT periphery_NN ._. A_DT lower_JJR percentage_NN of_IN hCARΔcyt_NN
          positive_JJ cells_NNS was_VBD observed_VBN in_IN the_DT CD_NNP 4_CD -_: CD_NNP 8_CD -_: double_JJ
          negative_JJ fraction_NN in_IN all_DT lines_NNS studied_VBN ,_, which_WDT likely_JJ
          reflects_VBZ the_DT heterogeneous_JJ nature_NN of_IN the_DT double_JJ negative_JJ
          population_NN ._. The_DT skewed_VBN pattern_NN of_IN thymocyte_NN development_NN
          toward_IN CD_NNP 4_CD +_NN single_JJ positive_NN in_IN each_DT of_IN the_DT lines_NNS was_VBD
          similar_JJ to_TO that_DT observed_VBD in_IN DO_NNP 11_CD ._. 10_CD ._. hCARΔcyt_NN -_: control_NN
          littermates_NNS (_( data_NNS not_RB shown_VBN )_) ._. Thus_RB ,_, in_IN the_DT three_CD distinct_JJ
          lines_NNS studied_VBN ,_, the_DT CD_NNP 2_CD promoter_NN /_NN LCR_NNP /_NN enhancer_NN directed_VBD the_DT
          expression_NN of_IN the_DT hCARΔcyt_NN transgene_NN to_TO the_DT T_NN cell_NN and_CC in_IN
          one_CD of_IN the_DT lines_NNS ,_, the_DT B_NNP cell_NN lineage_NN ._. Line_NNP 18_CD was_VBD chosen_VBN
          for_IN further_JJ study_NN as_IN the_DT recipient_NN of_IN adenoviral-mediated_JJ
          gene_NN delivery_NN due_JJ to_TO its_PRP$ uniform_NN ,_, T_NN cell-specific_JJ
          expression_NN of_IN the_DT hCARΔcyt_NN transgene_NN ._.
        
        
          Primary_JJ T_NN cells_NNS and_CC thymocytes_NNS from_IN DO_NNP 11_CD ._. hCARΔcyt_NN
          mice_NNS are_VBP efficiently_RB transduced_JJ by_IN adenoviral_NN
          vectors_NNS
          To_TO determine_VB whether_IN lymphocytes_NNS from_IN hCARΔcyt_NN ._. CD_NNP 2_CD
          transgenic_JJ mice_NNS were_VBD susceptible_JJ to_TO adenoviral_NN
          transduction_NN ,_, lymph_NN node_NN cells_NNS were_VBD isolated_VBN from_IN line_NN
          DO_NNP 11_CD ._. hCARΔcyt_NN ._. 18_CD and_CC incubated_JJ with_IN adenoviral_NN vectors_NNS
          designed_VBN to_TO express_VB GFP_NNP under_IN the_DT control_NN of_IN the_DT CMV_NNP 5_CD or_CC
          ubiquitin_NN (_( UbP_NNP )_) promoters_NNS (_( Fig_NNP ._. 2_LS A_DT )_) ._. Seventy_CD percent_NN of_IN
          resting_VBG CD_NNP 4_CD +_NN cells_NNS that_WDT were_VBD transduced_JJ with_IN the_DT
          Ad_NN 5_CD ._. UbP_NNP ._. GFP_NNP expressed_VBD the_DT GFP_NNP reporter_NN without_IN
          activation_NN ._. In_IN contrast_NN ,_, only_RB 36_CD %_NN of_IN resting_VBG CD_NNP 4_CD +_NN cells_NNS
          transduced_JJ with_IN the_DT Ad_NN 5_CD ._. CMV_NNP 5_CD ._. GFP_NNP were_VBD GFP_NNP +_NN ,_, and_CC the_DT mean_JJ
          fluorescence_NN intensity_NN was_VBD lower_RBR ,_, suggesting_VBG an_DT inability_NN
          of_IN the_DT CMV_NNP 5_CD promoter_NN to_TO induce_VB strong_JJ GFP_NNP expression_NN in_IN
          resting_VBG T_NN cells_NNS ._. Following_VBG activation_NN with_IN PMA_NNP and_CC
          ionomycin_NN ,_, CMV_NNP 5_CD -_: driven_VBN expression_NN of_IN GFP_NNP increased_VBD to_TO 81_CD %_NN
          of_IN the_DT CD_NNP 4_CD +_NN T_NN cells_NNS ._. A_DT small_JJ percentage_NN of_IN CD_NNP 4_CD -_: cells_NNS ,_,
          representing_VBG the_DT hCARΔcyt_NN +_NN CD_NNP 8_CD +_NN fraction_NN ,_, were_VBD transduced_JJ
          with_IN both_DT the_DT UbP_NNP and_CC CMV_NNP 5_CD viruses_NNS as_RB well_RB ._.
          To_TO determine_VB whether_IN adenoviral_NN transduction_NN changed_VBD
          their_PRP$ activation_NN status_NN ,_, resting_VBG CD_NNP 4_CD +_NN T_NN cells_NNS were_VBD
          examined_VBN for_IN expression_NN of_IN the_DT early_JJ activation_NN markers_NNS
          CD_NNP 62_CD L_NNP (_( L-_NNP selectin_NN )_) and_CC CD_NNP 25_CD (_( IL-_NNP 2_CD Rα_NNP )_) ._. After_IN transduction_NN
          with_IN Ad_NN 5_CD ._. UbP_NNP ._. GFP_NNP or_CC Ad_NN 5_CD ._. CMV_NNP 5_CD ._. GFP_NNP without_IN PMA_NNP /_NN ionomycin_NN ,_,
          the_DT GFP_NNP positive_JJ and_CC the_DT GFP_NNP negative_JJ fractions_NNS of_IN CD_NNP 4_CD
          +_NN cells_NNS were_VBD both_DT CD_NNP 62_CD L_NNP high_JJ and_CC CD_NNP 25_CD low_JJ ,_, confirming_VBG that_IN
          the_DT cells_NNS were_VBD initially_RB of_IN a_DT resting_VBG phenotype_NN and_CC that_DT
          adenoviral_NN transduction_NN did_VBD not_RB activate_VBP them_PRP ._. Upon_IN
          activation_NN with_IN PMA_NNP /_NN ionomycin_NN ,_, the_DT CD_NNP 4_CD +_NN T_NN cells_NNS
          down-regulated_JJ CD_NNP 62_CD L_NNP and_CC up-regulated_JJ CD_NNP 25_CD (_( Fig_NNP ._. 2_LS A_DT )_) ._.
          Control_NN T_NN cells_NNS from_IN hCARΔcyt_NN transgene-negative_JJ
          littermates_NNS had_VBD indistinguishable_JJ flow_NN cytometric_JJ profile_NN
          (_( data_NNS not_RB shown_VBN )_) ._.
          Because_IN the_DT expression_NN of_IN hCARΔcyt_NN was_VBD detected_VBN early_RB
          in_IN thymocyte_NN development_NN (_( Fig_NNP ._. 1_LS C_NNP )_) ,_, the_DT ability_NN of_IN these_DT
          cells_NNS to_TO be_VB transduced_JJ by_IN adenovirus_JJ was_VBD also_RB determined_VBN ._.
          Thymocytes_NNP from_IN line_NN 18_CD were_VBD incubated_JJ with_IN Ad_NN 5_CD ._. UbP_NNP ._. GFP_NNP
          as_IN stated_VBN above_IN ,_, and_CC were_VBD evaluated_VBN by_IN flow_NN cytometry_NN for_IN
          their_PRP$ expression_NN of_IN CD_NNP 4_CD ,_, CD_NNP 8_CD ,_, and_CC GFP_NNP (_( Fig_NNP ._. 2_LS B_NNP )_) ._.
          Seventy-five_NNP percent_NN of_IN the_DT CD_NNP 4_CD SP_NNP cells_NNS were_VBD transduced_JJ
          for_IN GFP_NNP expression_NN ,_, consistent_JJ with_IN the_DT transduction_NN
          frequency_NN of_IN CD_NNP 4_CD +_NN T_NN cells_NNS in_IN the_DT periphery_NN ._. Approximately_RB
          half_NN of_IN the_DT CD_NNP 8_CD SP_NNP could_MD be_VB transduced_JJ as_IN well_RB ._.
          Interestingly_RB ,_, whereas_IN a_DT high_JJ percentage_NN of_IN the_DT DN_NNP
          thymocytes_NNS expressed_VBD GFP_NNP after_IN transduction_NN (_( 75_CD %_NN )_) ,_, the_DT DP_NNP
          fraction_NN was_VBD relatively_RB refractory_JJ to_TO transduction_NN even_RB
          though_IN all_DT of_IN the_DT DP_NNP cells_NNS expressed_VBD hCARΔcyt_NN ;_: less_JJR than_IN
          10_CD %_NN of_IN the_DT transduced_JJ DP_NNP cells_NNS were_VBD GFP-positive_NNP
          irrespective_RB of_IN the_DT MOI_NNP tested_VBD (_( Fig_NNP ._. 2_LS Band_NNP data_NNS not_RB
          shown_VBN )_) ._.
        
        
          Adenoviral_NNP transduction_NN of_IN Th_NNP 1_CD and_CC Th_NNP 2_CD lines_NNS
          derived_VBN from_IN DO_NNP 11_CD ._. hCARΔcyt_NN transgenic_JJ mice_NNS
          To_TO examine_VB the_DT susceptibility_NN of_IN effector_NN T_NN cell_NN
          populations_NNS to_TO adenoviral_NN transduction_NN ,_, Th_NNP 1_CD and_CC Th_NNP 2_CD cells_NNS
          were_VBD derived_VBN from_IN DO_NNP 11_CD ._. hCARΔcyt_NN ._. 18_CD mice_NNS by_IN in_IN vitro_NN
          culture_NN under_IN polarizing_VBG cytokine_NN conditions_NNS [_NN 21_CD ]_NN ._. The_DT
          resulting_VBG Th_NNP 1_CD and_CC Th_NNP 2_CD lines_NNS were_VBD incubated_JJ with_IN
          Ad_NN 5_CD ._. UbP_NNP ._. GFP_NNP or_CC Ad_NN 5_CD ._. CMV_NNP 5_CD ._. GFP_NNP ,_, with_IN or_CC without_IN activation_NN
          with_IN PMA_NNP /_NN ionomycin_NN ,_, and_CC expression_NN of_IN GFP_NNP was_VBD measured_VBN by_IN
          flow_NN cytometry_NN 24_CD hours_NNS later_RB (_( Fig_NNP ._. 3_LS and_CC Table_NNP 1_LS )_) ._.
          Similar_JJ to_TO naïve_NN T_NN cells_NNS ,_, resting_VBG Th_NNP 1_CD and_CC Th_NNP 2_CD cells_NNS were_VBD
          readily_RB transduced_JJ by_IN Ad_NN 5_CD ._. UbP_NNP ._. GFP_NNP ,_, and_CC PMA_NNP /_NN ionomycin_NN
          activation_NN had_VBD little_JJ effect_NN on_IN either_DT the_DT frequency_NN or_CC
          expression_NN levels_NNS of_IN GFP_NNP positive_JJ cells_NNS ._. In_IN contrast_NN ,_,
          both_DT the_DT frequencies_NNS and_CC levels_NNS of_IN GFP_NNP expression_NN were_VBD
          increased_VBN in_IN Ad_NN 5_CD ._. CMV_NNP 5_CD ._. GFP-transduced_NNP Th_NNP 1_CD and_CC Th_NNP 2_CD lines_NNS
          following_VBG activation_NN with_IN PMA_NNP /_NN ionomycin_NN ,_, anti-_NN CD_NNP 3_CD or_CC OVA_NNP
          peptide_NN ._. Further_RB ,_, the_DT activation-induced_JJ expression_NN of_IN
          GFP_NNP by_IN cells_NNS transduced_JJ with_IN the_DT Ad_NN 5_CD ._. CMV_NNP 5_CD vector_NN yielded_VBD
          significantly_RB better_JJR expression_NN levels_NNS than_IN those_DT induced_VBN
          by_IN the_DT Ad_NN 5_CD ._. UbP_NNP vector_NN ._. Thus_RB ,_, both_DT Th_NNP 1_CD and_CC Th_NNP 2_CD effectors_NNS
          derived_VBN from_IN DO_NNP 11_CD ._. hCARΔcyt_NN mice_NNS are_VBP competent_JJ hosts_NNS for_IN
          adenoviral_NN transduction_NN ,_, and_CC were_VBD equivalent_JJ to_TO or_CC better_JJR
          than_IN naïve_NN DO_NNP 11_CD ._. hCARΔcyt_NN cells_NNS with_IN respect_NN to_TO their_PRP$
          transduction_NN efficiencies_NNS and_CC /_NN or_CC reporter_NN expression_NN
          levels_NNS ._.
        
        
          Adenoviral_NNP transduction_NN does_VBZ not_RB alter_VB the_DT
          functional_JJ responses_NNS or_CC differentiative_JJ potential_NN of_IN
          primary_JJ T_NN cells_NNS
          Although_IN adenoviral_NN transduction_NN did_VBD not_RB induce_VB
          detectable_JJ activation_NN of_IN resting_VBG ,_, naïve_NN CD_NNP 4_CD +_NN T_NN cells_NNS
          (_( Figure_NN 2_LS )_) ,_, we_PRP wished_VBD to_TO further_VB determine_VB whether_IN
          transduction_NN altered_VBD the_DT activation-induced_JJ functions_NNS of_IN
          this_DT population_NN ._. The_DT proliferative_JJ responses_NNS and_CC
          potential_JJ for_IN Th_NNP 1_CD and_CC Th_NNP 2_CD phenotype_NN development_NN were_VBD
          therefore_RB examined_VBN following_VBG adenoviral_NN transduction_NN ._. CD_NNP 4_CD
          +_NN T_NN cells_NNS isolated_VBN from_IN DO_NNP 11_CD ._. hCARΔcyt_NN ._. 18_CD mice_NNS were_VBD
          transduced_JJ with_IN Ad_NN 5_CD ._. UbP_NNP ._. GFP_NNP ,_, and_CC were_VBD sorted_VBN after_IN 24_CD
          hours_NNS based_VBN on_IN their_PRP$ expression_NN of_IN GFP_NNP ._. The_DT sorted_VBN cells_NNS
          were_VBD cultured_JJ with_IN antigen_NN presenting_VBG cells_NNS and_CC
          increasing_VBG concentrations_NNS of_IN OVA_NNP peptide_NN for_IN 3_CD days_NNS and_CC
          then_RB pulsed_JJ with_IN [_NN 3_CD H_NNP ]_NN thymidine_NN for_IN 24_CD hours_NNS ._. Figure_NN
          4_CD Ashows_NNP that_IN the_DT GFP_NNP positive_JJ population_NN of_IN Ad-transduced_NNP
          cells_NNS had_VBD a_DT comparable_JJ proliferative_JJ response_NN to_TO the_DT
          non-transduced_JJ GFP_NNP negative_JJ cells_NNS across_IN the_DT entire_JJ
          antigen_NN dose_NN range_NN ._. Thus_RB ,_, adenoviral_NN transduction_NN did_VBD not_RB
          significantly_RB affect_VB primary_JJ CD_NNP 4_CD T_NN cell_NN
          proliferation_NN ._.
          Transduced_NNP ,_, sorted_VBN GFP_NNP +_NN and_CC GFP_NNP -_: CD_NNP 4_CD T_NN cells_NNS were_VBD
          cultured_JJ under_IN Th_NNP 1_CD -_: /_NN Th_NNP 2_CD -_: polarizing_VBG conditions_NNS and_CC
          examined_VBD for_IN cytokine_NN production_NN following_VBG re-stimulation_JJ
          to_TO determine_VB potential_JJ effects_NNS of_IN adenoviral_NN transduction_NN
          on_IN effector_NN phenotype_NN development_NN (_( Figure_NN 4_CD B_NNP )_) ._. Following_VBG
          one_CD week_NN of_IN polarization_NN ,_, Th_NNP 1_CD and_CC Th_NNP 2_CD cells_NNS were_VBD tested_VBN
          by_IN ELISA_NNP for_IN their_PRP$ ability_NN to_TO produce_VB cytokines_NNS
          indicative_JJ of_IN the_DT two_CD different_JJ T_NN cell_NN subsets_NNS (_( Figure_NN
          4_CD B_NNP )_) ._. Th_NNP 1_CD -_: and_CC Th_NNP 2_CD -_: polarized_VBN cells_NNS from_IN both_DT the_DT
          transduced_JJ (_( GFP_NNP +_NN )_) and_CC non-transduced_JJ (_( GFP_NNP -_: )_) populations_NNS
          produced_VBD comparable_JJ amounts_NNS of_IN Th_NNP 1_CD -_: specific_JJ (_( IFN-γ_NNP )_) or_CC
          Th_NNP 2_CD -_: specific_JJ (_( IL-_NNP 4_CD and_CC IL-_NNP 10_CD )_) cytokines_NNS ,_, respectively_RB ._.
          Cytokine_NNP production_NN by_IN Th_NNP 1_CD -_: and_CC Th_NNP 2_CD -_: polarized_VBN DO_NNP 11_CD ._. 10_CD T_NN
          cells_NNS from_IN hCARΔcyt-negative_JJ littermate_NN controls_NNS was_VBD not_RB
          significantly_RB different_JJ (_( data_NNS not_RB shown_VBN )_) ._. Thus_RB ,_, neither_DT
          hCAR_NN expression_NN nor_CC adenoviral_NN transduction_NN alters_NNS the_DT
          naïve_NN T_NN cell_NN 's_POS potential_JJ for_IN Th_NNP 1_CD or_CC Th_NNP 2_CD phenotype_NN
          development_NN ._.
        
        
          In_IN vivo_NN trafficking_NN of_IN Ad-transduced_NNP CD_NNP 4_CD +_NN T_NN
          cells_NNS
          To_TO further_VB investigate_VB the_DT effects_NNS of_IN adenoviral_NN
          transduction_NN on_IN T_NN cell_NN biology_NN ,_, and_CC to_TO examine_VB the_DT
          possibility_NN that_DT hCAR_NN expression_NN (_( an_DT Ig_NNP superfamily_RB
          member_NN of_IN undetermined_JJ function_NN )_) might_MD alter_VB the_DT in_IN vivo_NN
          distribution_NN of_IN transduced_JJ T_NN cells_NNS ,_, we_PRP examined_VBD the_DT
          tissue_NN distribution_NN of_IN DO_NNP 11_CD ._. hCARΔcyt_NN T_NN cells_NNS following_VBG
          adoptive_JJ transfer_NN into_IN BALB_NNP /_NN c_SYM recipients_NNS ._. For_IN these_DT
          experiments_NNS ,_, we_PRP used_VBD line_NN 13_CD DO_NNP 11_CD ._. hCARΔcyt_NN Tg_NNP mice_NNS that_WDT
          have_VBP a_DT bimodal_NN distribution_NN of_IN hCAR_NN expression_NN to_TO provide_VB
          an_DT internal_JJ control_NN ,_, "_'' sham_NN transfection_NN "_'' population_NN ._. CD_NNP 4_CD
          +_NN cells_NNS were_VBD isolated_VBN from_IN DO_NNP 11_CD ._. hCARΔcyt_NN ._. 13_CD lymph_NN and_CC
          spleen_NN cells_NNS and_CC transduced_JJ with_IN Ad_NN 5_CD ._. UbP_NNP ._. GFP_NNP ._. Twenty-four_CD
          hours_NNS later_RB ,_, transduced_JJ T_NN cells_NNS were_VBD recovered_VBN and_CC
          examined_VBD for_IN GFP_NNP expression_NN by_IN flow_NN cytometry_NN prior_RB to_TO
          transfer_NN of_IN 5_CD ×_NN 10_CD 6_CD cells_NNS into_IN each_DT recipient_JJ mouse_NN ._. In_IN a_DT
          representative_NN experiment_NN shown_VBN in_IN Figure_NN 5_CD ,_, 45_CD %_NN percent_NN
          of_IN the_DT pre-transfer_JJ CD_NNP 4_CD +_NN cells_NNS expressed_VBD the_DT clonotypic_JJ
          marker_NN KJ-_NNP 126_CD and_CC of_IN these_DT cells_NNS ,_, 47_CD ._. 5_LS %_NN had_VBD been_VBN
          transduced_JJ for_IN GFP_NNP expression_NN (_( Fig_NNP ._. 5_LS A_DT ,_, top_JJ panel_NN )_) ._.
          Forty-eight_NNP hours_NNS after_IN I_PRP ._. V_NNP ._. injection_NN of_IN the_DT
          transduced_JJ (_( DO_NNP 11_CD ._. hCARΔcyt_NN ._. 13_CD )_) or_CC control_NN (_( DO_NNP 11_CD ._. 10_CD )_) cells_NNS ,_,
          recipient_JJ mice_NNS were_VBD sacrificed_JJ and_CC secondary_JJ lymphoid_NN
          tissues_NNS (_( lymph_NN nodes_NNS ,_, spleen_NN and_CC Peyer_NNP 's_POS patches_NNS )_) were_VBD
          divided_VBN for_IN detection_NN of_IN the_DT transferred_VBN KJ_NNP 1_CD -_: 26_CD +_NN and_CC GFP_NNP
          +_NN T_NN cells_NNS by_IN flow_NN cytometry_NN (_( Fig_NNP ._. 5_LS A_DT ,_, lower_JJR panel_NN )_) or_CC
          immuno-histochemistry_JJ (_( Fig_NNP ._. 5_LS B_NNP )_) ._. Flow_NNP cytometric_JJ analysis_NN
          determined_VBN that_IN the_DT transferred_VBN population_NN of_IN
          Ad-transduced_NNP cells_NNS from_IN DO_NNP 11_CD ._. hCARΔcyt_NN Tg_NNP donors_NNS retained_VBD
          the_DT pre-transfer_JJ frequencies_NNS of_IN GFP_NNP +_NN and_CC GFP_NNP -_: cells_NNS
          within_IN the_DT DO_NNP 11_CD ._. 10_CD T_NN cell_NN (_( CD_NNP 4_CD +_NN KJ_NNP 1_CD -_: 26_CD +_NN )_) fraction_NN and_CC
          were_VBD equivalent_JJ to_TO control_VB DO_NNP 11_CD ._. 10_CD cells_NNS with_IN respect_NN to_TO
          the_DT relative_JJ distribution_NN between_IN secondary_JJ lymphoid_NN
          organs_NNS (_( Fig_NNP ._. 5_LS A_DT &_CC 5_CD B_NNP ;_: data_NNS not_RB shown_VBN )_) ._. Thus_RB ,_, 51_CD ._. 5_LS %_NN of_IN
          the_DT recovered_VBN KJ_NNP 1_CD -_: 26_CD positive_JJ cells_NNS isolated_VBN from_IN pooled_VBN
          lymph_NN nodes_NNS expressed_VBD GFP_NNP ,_, compared_VBN to_TO a_DT pre-transfer_JJ
          frequency_NN of_IN 47_CD ._. 5_LS %_NN ._. Similar_JJ results_NNS were_VBD obtained_VBN in_IN
          recovered_VBD splenic_JJ tissues_NNS ,_, and_CC at_IN 72_CD and_CC 96_CD hours_NNS
          post-transfer_JJ (_( data_NNS not_RB shown_VBN )_) ._. There_EX was_VBD an_DT increase_NN in_IN
          the_DT level_NN of_IN GFP_NNP reporter_NN expression_NN by_IN Ad-transduced_NNP
          cells_NNS in_IN the_DT interval_NN between_IN transfer_NN and_CC recovery_NN
          (_( pre-transfer_JJ MFI_NNP :_: 75_CD ;_: post-transfer_JJ MFI_NNP :_: 320_CD )_) ,_,
          suggesting_VBG continued_VBN GFP_NNP transcription_NN in_IN vivo_NN ._. Thus_RB ,_,
          there_EX was_VBD no_DT preferential_JJ loss_NN or_CC increase_NN of_IN the_DT
          Ad-transduced_NNP cells_NNS in_IN vivo_NN ,_, nor_CC were_VBD there_EX gross_JJ
          differences_NNS in_IN trafficking_NN to_TO secondary_JJ lymphoid_NN
          tissues_NNS ._.
          To_TO determine_VB if_IN adenoviral_NN transduction_NN or_CC GFP_NNP
          reporter_NN expression_NN altered_VBD T_NN cell_NN trafficking_NN to_TO tissue_NN
          microenvironments_NNS ,_, recovered_VBD lymphoid_NN tissues_NNS were_VBD
          sectioned_JJ and_CC processed_VBN for_IN fluorescent_NN microscopic_JJ
          analysis_NN (_( Figure_NN 5_CD Band_NNP Table_NNP 2_LS )_) ._. A_DT double-label_JJ
          immunofluorescent_NN protocol_NN was_VBD developed_VBN to_TO permit_VB in_IN
          situ_NN localization_NN of_IN GFP_NNP +_NN or_CC KJ_NNP 1_CD -_: 26_CD +_NN T_NN cells_NNS and_CC B_NNP 220_CD +_NN B_NNP
          cells_NNS in_IN fixed_VBN ,_, frozen_VBN tissue_NN sections_NNS (_( Figure_NN 5_CD B_NNP ,_, and_CC
          data_NNS not_RB shown_VBN )_) ._. Irrespective_NNP of_IN the_DT population_NN of_IN T_NN
          cells_NNS transferred_VBN (_( DO_NNP 11_CD ._. 10_CD wild-type_JJ control_NN or_CC
          Ad_NN 5_CD ._. UbC_NNP ._. GFP-transduced_NNP DO_NNP 11_CD ._. hCARΔcyt_NN )_) ,_, a_DT similar_JJ
          distribution_NN of_IN KJ_NNP 1_CD -_: 26_CD +_NN and_CC GFP_NNP +_NN T_NN cells_NNS was_VBD found_VBN within_IN
          the_DT secondary_JJ lymphoid_NN tissue_NN microenvironments_NNS ._. In_IN the_DT
          spleen_NN ,_, KJ_NNP 1_CD -_: 26_CD +_NN or_CC GFP_NNP +_NN cells_NNS were_VBD primarily_RB located_VBN
          within_IN the_DT periarterial_NN lymphoid_NN sheaths_NNS (_( PALS_NNP )_) ,_, with_IN
          fewer_RBR positive_JJ cells_NNS in_IN the_DT marginal_JJ zones_NNS ,_, and_CC only_RB
          scattered_VBN positive_JJ cells_NNS in_IN the_DT red_JJ pulp_NN (_( Table_NNP 2_LS )_) ._.
          Relatively_RB few_JJ positive_JJ cells_NNS were_VBD detected_VBN within_IN the_DT B_NNP
          cell_NN follicles_NNS ,_, although_IN positive_JJ cells_NNS could_MD be_VB found_VBN in_IN
          the_DT PALS_NNP ,_, at_IN the_DT border_NN with_IN B_NNP cell_NN follicles_NNS ._. Similarly_RB ,_,
          in_IN lymph_NN nodes_NNS and_CC Peyer_NNP 's_POS patches_NNS ,_, the_DT wild-type_JJ and_CC
          Ad-transduced_NNP transgenic_JJ T_NN cells_NNS localized_JJ primarily_RB to_TO
          paracortical_JJ T_NN cell_NN areas_NNS ._. Collectively_RB ,_, these_DT data_NNS
          indicate_VBP that_IN neither_DT hCARΔcyt_NN or_CC GFP_NNP expression_NN nor_CC
          adenoviral_NN transduction_NN affects_VBZ survival_NN or_CC trafficking_NN
          of_IN adoptively_RB transferred_VBN cells_NNS for_IN at_IN least_JJS 4_CD days_NNS in_IN
          vivo_NN ._.
        
      
      
        Discussion_NNP
        The_DT introduction_NN of_IN transgenic_JJ systems_NNS adapted_VBN to_TO take_VB
        advantage_NN of_IN adenoviral_NN gene_NN delivery_NN technology_NN offers_VBZ an_DT
        attractive_JJ adjunct_NN to_TO existing_VBG gene_NN delivery_NN strategies_NNS for_IN
        studies_NNS of_IN lymphocyte_NN biology_NN ._. In_IN an_DT effort_NN to_TO facilitate_VB
        gene_NN transfer_NN into_IN primary_JJ lymphocytes_NNS ,_, we_PRP and_CC others_NNS [_NN 14_CD
        15_CD ]_NN have_VBP employed_VBN different_JJ strategies_NNS to_TO engineer_VB
        transgenic_JJ mice_NNS that_WDT express_VBP the_DT human_JJ adenoviral_NN receptor_NN ,_,
        hCAR_NN ,_, on_IN murine_NN lymphocytes_NNS ._. Here_RB we_PRP report_VBP the_DT
        characterization_NN of_IN three_CD new_JJ transgenic_JJ lines_NNS that_WDT express_VBP
        a_DT cytoplasmic-tail_JJ truncated_JJ hCAR_NN under_IN control_NN of_IN hCD_NN 2_CD
        gene_NN regulatory_JJ elements_NNS ,_, and_CC demonstrate_VB their_PRP$ utility_NN for_IN
        gene_NN transfer_NN studies_NNS of_IN primary_JJ T_NN cells_NNS and_CC thymocytes_NNS ._. In_IN
        agreement_NN with_IN previous_JJ studies_NNS using_VBG human_JJ CD_NNP 2_CD mini-gene_JJ
        expression_NN cassette_NN [_NN 16_CD 17_CD 18_CD ]_NN ,_, the_DT truncated_JJ hCAR_NN
        transgene_NN was_VBD expressed_VBN in_IN all_DT cells_NNS of_IN the_DT T_NN cell_NN lineage_NN ,_,
        and_CC except_IN for_IN transgenic_JJ line_NN 6_CD (_( hCARΔcyt_NN ._. CD_NNP 2_CD ._. 6_CD )_) ,_, in_IN which_WDT
        there_EX was_VBD expression_NN on_IN mature_VBP B_NNP cells_NNS as_RB well_RB as_IN T_NN cells_NNS ,_,
        hCAR_NN was_VBD not_RB expressed_VBN by_IN non-_NN T_NN cells_NNS ._. Importantly_NNP ,_, the_DT
        expression_NN of_IN hCARΔcyt_NN by_IN T_NN cells_NNS was_VBD stable_JJ and_CC high-level_JJ
        at_IN all_DT stages_NNS of_IN development_NN ,_, from_IN double-negative_JJ
        thymocytes_NNS to_TO Th_NNP 1_CD and_CC Th_NNP 2_CD effectors_NNS ._. With_IN the_DT possible_JJ
        exception_NN of_IN double_JJ positive_JJ thymocytes_NNS (_( see_VB below_IN )_) ,_,
        reporter_NN expression_NN by_IN transduced_JJ hCARΔcyt-positive_JJ cells_NNS
        at_IN each_DT of_IN these_DT developmental_NN stages_NNS was_VBD very_RB efficient_JJ ._.
        Thus_RB ,_, it_PRP is_VBZ possible_JJ to_TO target_VB adenoviral_NN transduction_NN to_TO
        the_DT T_NN cell_NN compartment_NN in_IN vitro_NN and_CC in_IN vivo_NN ._. Of_IN particular_JJ
        note_NN ,_, the_DT level_NN of_IN expression_NN of_IN hCARΔcyt_NN was_VBD not_RB
        significantly_RB lower_JJR for_IN double-negative_JJ and_CC double-positive_JJ
        thymocyte_NN populations_NNS in_IN line_NN hCARΔcyt_NN ._. CD_NNP 2_CD ._. 18_CD mice_NNS ,_,
        contrary_JJ to_TO what_WP was_VBD observed_VBN previously_RB [_NN 15_CD ]_NN ._. The_DT
        high-level_JJ expression_NN of_IN hCARΔcyt_NN by_IN double-negative_JJ (_( CD_NNP 4_CD
        -_: CD_NNP 8_CD -_: )_) thymocytes_NNS rendered_VBD this_DT population_NN readily_RB
        transducible_JJ ,_, suggesting_VBG that_IN these_DT early_JJ thymocytes_NNS
        express_VBP sufficient_JJ integrin_NN co-receptors_JJ (_( e_SYM ._. g_SYM ._. α_NN 
        v_NN β_NN 3_CD or_CC α_NN 
        v_NN β_NN 5_LS )_) for_IN adenoviral_NN entry_NN and_CC making_VBG
        this_DT a_DT useful_JJ model_NN for_IN early_JJ thymocyte_NN gene_NN targeting_VBG
        Despite_IN expression_NN of_IN levels_NNS of_IN hCARΔcyt_NN comparable_JJ to_TO
        that_DT of_IN double-negative_JJ and_CC single-positive_JJ thymocytes_NNS ,_,
        double-positive_JJ thymocytes_NNS were_VBD relatively_RB refractory_JJ to_TO
        reporter_NN expression_NN following_VBG transduction_NN with_IN either_DT the_DT
        Ad_NN 5_CD ._. UbP_NNP ._. GFP_NNP or_CC Ad_NN 5_CD ._. CMV_NNP 5_CD ._. GFP_NNP vector_NN ._. The_DT lack_NN of_IN reporter_NN
        expression_NN could_MD reflect_VB poor_JJ entry_NN of_IN adenovirus_JJ in_IN this_DT
        population_NN or_CC poor_JJ transcriptional_NN activity_NN of_IN the_DT
        promoters_NNS used_VBN (_( UbP_NNP and_CC CMV_NNP 5_LS )_) ,_, among_IN other_JJ possibilites_NNS ._.
        Given_VBN the_DT comparable_JJ levels_NNS of_IN hCARΔcyt_NN expression_NN by_IN
        double-positive_JJ and_CC double-negative_JJ or_CC single_JJ positive_JJ
        thymocytes_NNS ,_, it_PRP is_VBZ unlikely_JJ that_IN viral_JJ entry_NN is_VBZ limiting_VBG in_IN
        these_DT cells_NNS ,_, although_IN this_DT has_VBZ not_RB been_VBN formally_RB tested_VBN ._. We_PRP
        favor_VBP the_DT possibility_NN that_IN the_DT poor_JJ reporter_NN expression_NN
        reflects_VBZ inefficient_JJ transcriptional_NN activity_NN of_IN these_DT
        promoters_NNS at_IN this_DT developmental_NN stage_NN ._. In_IN this_DT same_JJ vein_NN ,_,
        expression_NN of_IN the_DT GFP_NNP reporter_NN by_IN freshly_RB isolated_VBN mature_VBP T_NN
        cells_NNS transduced_JJ with_IN the_DT Ad_NN 5_CD ._. UbP_NNP ._. GFP_NNP vector_NN was_VBD very_RB
        efficient_JJ ,_, while_IN the_DT Ad_NN 5_CD ._. CMV_NNP 5_CD ._. GFP_NNP vector_NN required_VBD a_DT
        post-transduction_JJ activation_NN of_IN T_NN cells_NNS to_TO induce_VB optimal_NN
        expression_NN of_IN GFP_NNP [_NN 14_CD 15_CD ]_NN ._. On_IN the_DT contrary_NN ,_, the_DT CMV_NNP 5_CD
        promoter_NN yielded_VBD better_JJR reporter_NN expression_NN in_IN activated_VBN ,_,
        transduced_JJ Th_NNP 1_CD and_CC Th_NNP 2_CD cells_NNS ._. Thus_RB ,_, the_DT choice_NN of_IN promoter_NN
        will_MD need_VB to_TO be_VB optimized_JJ for_IN each_DT adenoviral_NN vector_NN
        depending_VBG on_IN the_DT developmental_NN stage_NN and_CC specific_JJ purpose_NN
        for_IN its_PRP$ use_NN ._. Studies_NNS with_IN other_JJ promoter_NN elements_NNS (_( e_SYM ._. g_SYM ._.
        CD_NNP 2_LS )_) are_VBP in_IN progress_NN and_CC should_MD be_VB informative_JJ ._.
        Interestingly_RB ,_, the_DT bimodal_NN pattern_NN of_IN transgene_NN
        expression_NN by_IN T_NN cells_NNS and_CC thymocytes_NNS from_IN line_NN
        hCARΔcyt_NN ._. CD_NNP 2_CD ._. 13_CD suggested_VBD some_DT positional_JJ effect_NN
        variegation_NN (_( PEV_NNP )_) of_IN the_DT transgene_NN ,_, an_DT effect_NN not_RB
        previously_RB reported_VBD in_IN trangenes_NNS that_WDT include_VBP the_DT entire_JJ
        CD_NNP 2_CD LCR_NNP [_NN 17_CD 18_CD ]_NN ._. Further_RB ,_, we_PRP have_VBP noticed_VBN that_IN the_DT
        percentage_NN of_IN hCARΔcyt_NN positive_JJ T_NN cells_NNS in_IN the_DT line_NN
        hCARΔcyt_NN ._. CD_NNP 2_CD ._. 13_CD increased_VBN with_IN successive_JJ generations_NNS of_IN
        back-cross_JJ of_IN the_DT original_JJ hCARΔcyt_NN founder_NN (_( B_NNP 6_CD xSJL_NN F_NN 1_LS )_)
        onto_IN a_DT BALB_NNP /_NN c_SYM background_NN ,_, reflecting_VBG a_DT strain_NN background_NN
        effect_NN of_IN the_DT PEV_NNP (_( data_NNS not_RB shown_VBN )_) ._. Although_IN the_DT mechanism_NN
        of_IN this_DT expression_NN heterogeneity_NN is_VBZ not_RB clear_JJ ,_, it_PRP is_VBZ
        fortuitous_JJ in_IN providing_VBG different_JJ lines_NNS that_WDT offer_NN distinct_JJ
        targeting_VBG profiles_NNS ._. Accordingly_RB ,_, it_PRP should_MD prove_VB possible_JJ
        to_TO target_VB both_DT B_NNP and_CC T_NN cells_NNS in_IN line_NN hCARΔcyt_NN ._. CD_NNP 2_CD ._. 6_CD mice_NNS ,_,
        whereas_IN line_NN hCARΔcyt_NN ._. CD_NNP 2_CD ._. 13_CD mice_NNS can_MD be_VB exploited_VBN to_TO
        perform_VB transduction_NN studies_NNS in_IN which_WDT there_EX is_VBZ an_DT hCARΔcyt_NN
        negative_JJ population_NN to_TO serve_VB as_IN an_DT internal_JJ control_NN (_( Figure_NN
        5_LS )_) ._.
        An_DT important_JJ consideration_NN at_IN the_DT outset_NN of_IN these_DT
        studies_NNS concerned_VBD the_DT possibility_NN that_IN ectopic_JJ hCAR_NN
        expression_NN or_CC adenoviral_NN transduction_NN might_MD affect_VB the_DT
        normal_JJ development_NN and_CC /_NN or_CC function_NN of_IN T_NN cells_NNS ._. For_IN this_DT
        reason_NN ,_, we_PRP chose_VBD to_TO use_VB a_DT truncated_JJ variant_NN of_IN hCAR_NN to_TO
        preclude_VB possible_JJ signaling_VBG by_IN this_DT molecule_NN [_NN 13_CD ]_NN ._. As_IN
        evidenced_VBN by_IN the_DT functional_JJ data_NN reported_VBD herein_NN ,_, and_CC those_DT
        from_IN previous_JJ reports_NNS [_NN 14_CD 15_CD ]_NN ,_, there_EX does_VBZ not_RB appear_VB to_TO
        be_VB an_DT adverse_JJ effect_NN of_IN either_DT hCARΔcyt_NN expression_NN or_CC
        adenoviral_NN transduction_NN on_IN T_NN cell_NN activation_NN ,_, development_NN
        or_CC function_NN ._. The_DT antigen-induced_JJ proliferative_JJ responses_NNS of_IN
        naïve_NN DO_NNP 11_CD ._. hCARΔcyt_NN T_NN cells_NNS were_VBD comparable_JJ to_TO those_DT of_IN
        non-h_JJ CAR_NNP DO_NNP 11_CD ._. 10_CD littermates_NNS ,_, and_CC the_DT differentiative_JJ
        potential_NN of_IN transduced_JJ naïve_NN T_NN cells_NNS into_IN Th_NNP 1_CD or_CC Th_NNP 2_CD
        effectors_NNS was_VBD not_RB compromised_VBN ._. While_IN at_IN higher_JJR
        multiplicities_NNS of_IN adenoviral_NN infection_NN (_( MOIs_NNP )_) than_IN those_DT
        required_JJ for_IN efficient_JJ transduction_NN there_EX were_VBD deleterious_JJ
        effects_NNS on_IN naïve_NN T_NN cell_NN viability_NN (_( data_NNS not_RB shown_VBN )_) ,_, at_IN the_DT
        MOIs_NNP used_VBD we_PRP saw_VBD no_DT decrease_NN in_IN cell_NN viability_NN or_CC function_NN ._.
        Further_RB ,_, adenoviral_NN transduction_NN of_IN resting_VBG ,_, naïve_NN T_NN cells_NNS
        exerted_VBN no_DT detectable_JJ intrinsic_JJ activation_NN of_IN these_DT cells_NNS ,_,
        suggesting_VBG that_DT adenoviral_NN delivery_NN of_IN genes_NNS of_IN interest_NN to_TO
        non-cycling_JJ T_NN cells_NNS will_MD permit_VB loss_NN or_CC gain_NN of_IN function_NN
        studies_NNS prior_RB to_TO antigen-_NN or_CC mitogen-driven_JJ
        stimulation_NN ._.
        Ad-transduced_NNP DO_NNP 11_CD ._. hCARΔcyt_NN trafficked_JJ normally_RB to_TO
        secondary_JJ lymphoid_NN organs_NNS following_VBG adoptive_JJ transfer_NN ,_,
        indicating_VBG that_IN neither_DT hCARΔcyt_NN nor_CC adenoviral_NN
        transduction_NN altered_VBD normal_JJ in_IN vivo_NN migration_NN patterns_NNS ._.
        This_DT affords_NNS the_DT opportunity_NN to_TO examine_VB the_DT in_IN vivo_NN
        responses_NNS of_IN transduced_JJ ,_, naïve_NN or_CC effector_NN T_NN cells_NNS
        following_VBG ex_FW vivo_NN gene_NN transfer_NN ._. Limitations_NNPS in_IN previous_JJ
        studies_NNS of_IN in_IN vivo_NN adenoviral_NN transduction_NN have_VBP been_VBN the_DT
        poor_JJ stability_NN of_IN adenoviral_NN transduction_NN in_IN dividing_VBG cells_NNS
        and_CC the_DT induction_NN of_IN cytotoxic_JJ immune_JJ responses_NNS to_TO
        adenoviral_NN gene_NN products_NNS ._. We_PRP observed_VBD no_DT decrement_NN in_IN GFP_NNP
        expression_NN by_IN adoptively_RB transferred_VBN cells_NNS as_RB long_RB as_IN 4_CD
        days_NNS following_VBG transfer_NN (_( data_NNS not_RB shown_VBN )_) ,_, but_CC have_VBP not_RB yet_RB
        examined_VBD later_RB time_NN points_NNS ._. Wan_NNP et_CC al_NN ._. reported_VBD accelerated_VBN
        loss_NN of_IN Ad-transduced_NNP cells_NNS relative_JJ to_TO controls_NNS via_IN an_DT
        immune-mediated_JJ mechanism_NN [_NN 15_CD ]_NN suggesting_VBG limitations_NNS for_IN
        long-term_JJ adoptive_JJ transfer_NN studies_NNS into_IN immune-competent_JJ
        recipients_NNS ._. It_PRP is_VBZ unclear_JJ at_IN present_JJ how_WRB immune_JJ responses_NNS
        to_TO Ad-transduced_NNP T_NN cells_NNS might_MD affect_VB their_PRP$ in_IN vivo_NN
        function_NN ,_, but_CC the_DT ability_NN to_TO examine_VB early_RB in_IN vivo_NN
        responses_NNS following_VBG adoptive_JJ transfers_NNS for_IN even_RB 3_CD -_: 4_CD days_NNS
        should_MD prove_VB valuable_JJ ,_, and_CC transfers_NNS into_IN immune-deficient_JJ
        recipients_NNS should_MD facilitate_VB long-term_JJ in_IN vivo_NN studies_NNS ._.
        Further_RB ,_, continued_VBN advances_NNS in_IN the_DT development_NN of_IN "_'' gutless_JJ "_''
        adenoviral_NN vectors_NNS that_WDT avoid_VBP expression_NN of_IN cytotoxic_JJ
        antigenic_JJ targets_NNS may_MD alleviate_VB immune_JJ clearance_NN problems_NNS [_NN
        22_CD 23_CD 24_CD ]_NN ._.
      
      
        Conclusions_NNP
        The_DT hCARΔcyt_NN ._. CD_NNP 2_CD transgenic_JJ lines_NNS reported_VBD here_RB offer_NN
        unique_JJ properties_NNS that_WDT will_MD be_VB advantageous_JJ for_IN many_JJ T_NN cell_NN
        transduction_NN studies_NNS ._. These_DT models_NNS offer_VBP several_JJ advantages_NNS
        over_IN existing_VBG approaches_NNS for_IN short-term_JJ gene_NN delivery_NN into_IN
        primary_JJ T_NN cells_NNS ,_, principal_NN of_IN which_WDT is_VBZ the_DT capacity_NN for_IN
        high-efficiency_JJ transduction_NN of_IN T_NN cells_NNS in_IN G_NNP 0_CD or_CC G_NNP 1_CD of_IN cell_NN
        cycle_NN ._. The_DT introduction_NN of_IN the_DT hCARΔcyt_NN ._. CD_NNP 2_CD transgene_NN into_IN
        TCR_NNP transgenic_JJ lines_NNS ,_, such_JJ as_IN the_DT DO_NNP 11_CD ._. 10_CD model_NN reported_VBD
        here_RB ,_, will_MD provide_VB a_DT powerful_JJ system_NN for_IN T_NN cell_NN
        developmental_NN studies_NNS ._. Due_JJ to_TO their_PRP$ high_JJ immunogenicity_NN and_CC
        their_PRP$ extra-chromosomal_JJ replication_NN ,_, the_DT current_JJ adenoviral_NN
        vectors_NNS may_MD not_RB be_VB appropriate_JJ for_IN long-term_JJ transduction_NN
        in-vivo_JJ but_CC improvement_NN in_IN vector_NN design_NN and_CC adoptive_JJ
        transfer_NN into_IN immunodeficient_NN hosts_NNS may_MD facilitate_VB
        experiments_NNS in_IN the_DT future_NN ._. The_DT development_NN of_IN newer_JJR
        recombinant_JJ adenoviruses_NNS containing_VBG elements_NNS for_IN
        epichromosomal_NN replication_NN may_MD alleviate_VB limitations_NNS that_WDT
        prevent_VBP more_RBR stable_JJ in_IN vivo_NN expression_NN in_IN dividing_VBG lymphoid_NN
        cells_NNS derived_VBN from_IN hCAR_NN transgenic_JJ mice_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Mice_NNS
          DO_NNP 11_CD ._. 10_CD TCR_NNP transgenic_JJ mice_NNS specific_JJ for_IN ovalbumin_NN
          peptide_NN residues_NNS 323_CD -_: 339_CD (_( OVA_NNP 323_CD -_: 339_CD )_) and_CC restricted_VBN by_IN
          I-A_NNP d_SYM [_NN 20_CD ]_NN were_VBD backcrossed_JJ onto_IN BALB_NNP /_NN cJ_NN background_NN
          (_( >_NN 16_CD generations_NNS )_) ._. Mice_NNS were_VBD screened_VBD for_IN TCR_NNP
          transgene_NN expression_NN by_IN two-color_JJ flow_NN cytometric_JJ
          analysis_NN of_IN peripheral_JJ blood_NN lymphocytes_NNS stained_JJ with_IN
          anti-_NN CD_NNP 4_CD and_CC the_DT anti-_NN DO_NNP 11_CD ._. 10_CD TCR_NNP mAb_NN ,_, KJ_NNP 1_CD -_: 26_CD [_NN 25_CD ]_NN ._.
          hCARΔcyt_NN transgenic_JJ mice_NNS were_VBD crossed_VBN with_IN BALB_NNP /_NN c_SYM DO_NNP 11_CD ._. 10_CD
          TCR_NNP Tg_NNP mice_NNS for_IN at_IN least_JJS 5_CD generations_NNS and_CC used_VBN at_IN 4_CD -_: 6_CD
          weeks_NNS of_IN age_NN ._. BALB_NNP /_NN cJ_NN mice_NNS were_VBD purchased_VBN from_IN the_DT
          Jackson_NNP Laboratory_NNP (_( Bar_NNP Harbor_NNP ,_, ME_NNP )_) and_CC were_VBD used_VBN at_IN 6_CD -_: 10_CD
          weeks_NNS of_IN age_NN ._. All_DT mice_NNS were_VBD maintained_VBN in_IN a_DT specific_JJ
          pathogen-free_JJ facility_NN at_IN the_DT University_NNP of_IN Alabama_NNP at_IN
          Birmingham_NNP and_CC treated_VBN according_VBG to_TO the_DT Animal_NNP Care_NNP
          Guidelines_NNS adopted_VBN by_IN this_DT institution_NN ._.
        
        
          Antibodies_NNP and_CC reagents_NNS
          The_DT RmcB_NNP (_( anti-h_JJ CAR_NNP )_) (_( ATCC_NNP ,_, [_NN 26_CD ]_NN )_) and_CC the_DT KJ_NNP 1_CD -_: 26_CD
          monoclonal_NN antibodies_NNS (_( anti-_NN DO_NNP 11_CD ._. 10_CD TCR_NNP )_) were_VBD purified_JJ
          from_IN ascites_NNS and_CC conjugated_JJ with_IN fluorescein_NN
          isothiocyanate_NN (_( FITC_NNP )_) ,_, biotin_NN or_CC phycoerythrin_NN (_( PE_NNP )_) by_IN
          Dr_NNP ._. Roger_NNP Lallone_NNP (_( Brookwood_NNP Biomedical_NNP ;_: Birmingham_NNP ,_, AL_NNP )_) ._.
          Purified_NNP anti-_NN CD_NNP 3_CD (_( 17_CD A_DT 2_LS )_) ,_, anti-_NN IL-_NNP 4_CD (_( 11_CD B_NNP 11_CD and_CC
          BVD_NNP 6_CD -_: 24_CD G_NNP 2_LS )_) ,_, anti-_NN IL-_NNP 10_CD (_( JES_NNP 5_CD -_: 2_CD A_DT 5_CD and_CC JES_NNP 5_CD -_: 16_CD E_NNP 3_LS )_) ,_,
          anti-_NN IL-_NNP 12_CD (_( C_NNP 17_CD ._. 8_CD )_) and_CC anti-_NN IFN-γ_NNP ,_, PE-conjugated_NNP anti-_NN CD_NNP 4_CD
          (_( GK_NNP 1_CD ._. 5_LS )_) ,_, biotin-conjugated_JJ anti-_NN CD_NNP 19_CD (_( 1_CD D_NNP 3_LS )_) ,_,
          anti-_NN CD_NNP 45_CD R_NN /_NN B_NNP 220_CD (_( RA_NNP 3_CD -_: 6_CD B_NNP 2_LS )_) ,_, anti-_NN CD_NNP 8_CD (_( 53_CD -_: 6_CD ._. 72_CD )_) ,_, anti-_NN CD_NNP 25_CD
          (_( 7_CD D_NNP 4_LS )_) and_CC anti-_NN CD_NNP 62_CD L_NNP /_NN L-_NNP selectin_NN (_( MEL-_NNP 14_CD )_) ,_, Cy-_NNP Chrome_NNP and_CC
          PE-labeled_NNP streptavidin_NN were_VBD purchased_VBN from_IN PharMingen_NNP
          (_( San_NNP Diego_NNP ,_, CA_NNP )_) ._. Recombinant_NNP murine_NN IL-_NNP 4_CD and_CC IL-_NNP 12_CD were_VBD
          purchased_VBN from_IN R_NN &_CC D_NNP Systems_NNPS Inc_NNP ._. (_( Minneapolis_NNP ,_, MN_NNP )_) ._.
          Phorbol_NNP 12_CD -_: myristate_NN 13_CD -_: acetate_NN (_( PMA_NNP )_) and_CC ionomycin_NN were_VBD
          purchased_VBN from_IN Sigma_NNP (_( St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._.
        
        
          Generation_NNP of_IN hCARΔcyt_NN transgenic_JJ mice_NNS
          DNA_NNP encoding_VBG the_DT extracellular_NN and_CC transmembrane_NN
          domain_NN of_IN the_DT hCAR_NN was_VBD obtained_VBN by_IN PCR_NNP amplification_NN of_IN a_DT
          human_JJ CAR_NNP cDNA_NN [_NN 9_CD ]_NN kindly_RB provided_VBN by_IN Dr_NNP ._. Jeffrey_NNP
          Bergelson_NNP ,_, (_( Children_NNP 's_POS Hospital_NNP of_IN Philadelphia_NNP ,_,
          Philadelphia_NNP ,_, PA_NNP )_) ._. The_DT forward_JJ primer_NN ,_,
          5_CD '_POS ACTGACGAATTCAGCCACCATGGCGCTCCTGCTGTGC_NNP 3_CD '_POS introduced_VBD an_DT
          EcoRI_NNP site_NN and_CC the_DT reverse_JJ primer_NN ,_,
          5_CD '_POS GTCAGTCCCGGGTCAGTCAGCTACTTTTTACGACAGCAAAAGAT_NNP 3_CD '_POS
          introduced_VBN stop_NN codons_NNS in_IN three_CD reading_NN frames_NNS and_CC a_DT SmaI_NNP
          site_NN ._. The_DT resulting_VBG fragment_NN (_( hCARΔcyt_NN )_) was_VBD restriction_NN
          endonuclease_NN digested_VBN and_CC subcloned_JJ into_IN the_DT EcoRI_NNP /_NN SmaI_NNP
          site_NN of_IN the_DT VA_NNP human_JJ CD_NNP 2_CD mini-gene_JJ containing_VBG the_DT human_JJ
          CD_NNP 2_CD promoter_NN and_CC 3_CD '_POS LCR_NNP [_NN 16_CD ]_NN ._. Automated_NNP sequencing_VBG
          (_( Applied_NNP Biosystems_NNP ,_, Foster_NNP City_NNP ,_, CA_NNP ;_: University_NNP of_IN
          Alabama_NNP at_IN Birmingham_NNP Department_NNP of_IN Microbiology_NNP
          sequencing_VBG facility_NN )_) of_IN the_DT entire_JJ construct_VB confirmed_VBD
          its_PRP$ accuracy_NN ._. A_DT KpnI_NNP /_NN XbaI_NNP digest_VB liberated_VBD the_DT
          CD_NNP 2_CD /_NN hCARΔcyt_NN transgene_NN from_IN the_DT vector_NN backbone_NN and_CC the_DT
          transgene_NN was_VBD subsequently_RB microinjected_JJ into_IN fertilized_VBN
          oocytes_NNS by_IN the_DT UAB_NNP ES_NNP /_NN Transgenic_NNP facility_NN ._.
        
        
          Adenoviruses_NNP
          Ad_NN 5_CD ._. CMV_NNP 5_CD ._. GFP_NNP adenovirus_JJ ,_, with_IN an_DT improved_VBN
          cytomegalovirus_JJ promoter_NN (_( CMV_NNP 5_LS )_) expressing_VBG enhanced_VBN green_JJ
          fluorescent_NN protein_NN (_( GFP_NNP )_) ,_, was_VBD purchased_VBN from_IN Quantum_NNP
          Biotechnology_NNP (_( Qbiogen_NNP ,_, Carlsbad_NNP ,_, CA_NNP )_) ._. The_DT Ad_NN 5_CD ._. UbP_NNP ._. GFP_NNP
          expressing_VBG an_DT enhanced_VBN GFP_NNP under_IN the_DT control_NN of_IN a_DT human_JJ
          ubiquitin_NN promoter_NN (_( UbP_NNP )_) [_NN 27_CD ]_NN was_VBD kindly_RB provided_VBN by_IN
          Dr_NNP ._. J_NNP ._. DeGregori_NNP (_( University_NNP of_IN Colorado_NNP Health_NNP Science_NNP
          Center_NNP ,_, Denver_NNP ,_, CO_NNP )_) ._. After_IN large-scale_JJ production_NN ,_,
          adenoviruses_NNS were_VBD purified_JJ by_IN double_JJ cesium_NN chloride_NN
          gradient_NN [_NN 7_CD ]_NN ,_, dialyzed_JJ in_IN 10_CD %_NN glycerol_NN /_NN 10_CD mM_NN HEPES_NNP /_NN 0_CD ._. 5_LS
          mM_NN MgCl_NNP 
          2_CD and_CC stored_VBD in_IN viral_JJ preservation_NN
          medium_NN (_( 25_CD %_NN glycerol_NN /_NN 5_CD mM_NN Tris_NNP pH_NN 8_CD /_NN 50_CD mM_NN NaCl_NNP /_NN 0_CD ._. 05_CD %_NN BSA_NNP )_)
          until_IN use_NN ._. Viral_NNP titers_NNS were_VBD determined_VBN by_IN OD_NNP measurement_NN
          and_CC limiting_VBG dilution_NN analysis_NN of_IN GFP_NNP expression_NN by_IN
          transduced_JJ 293_CD cells_NNS following_VBG Quantum_NNP 's_POS AdEasy_NNP TCID_NNP 
          50_CD protocol_NN ._.
        
        
          Flow_NNP cytometric_JJ analysis_NN
          Splenocytes_NNP or_CC lymph_NN node_NN cells_NNS were_VBD stained_JJ for_IN flow_NN
          cytometry_NN with_IN the_DT PE-_NNP or_CC biotin-conjugated_JJ monoclonal_NN
          antibodies_NNS indicated_VBD in_IN the_DT appropriate_JJ figure_NN legends_NNS as_RB
          previously_RB described_VBD [_NN 28_CD ]_NN ._. Cells_NNP stained_JJ with_IN
          biotinylated_JJ primary_JJ antibody_NN were_VBD detected_VBN with_IN
          streptavidin-_NN Cy-_NNP Chrome_NNP (_( Pharmingen_NNP )_) ._. GFP_NNP expression_NN was_VBD
          detected_VBN in_IN the_DT FL_NNP 1_CD channel_NN ._. For_IN analytical_JJ flow_NN
          cytometry_NN ,_, 10_CD ,_, 000_CD events_NNS with_IN forward_RB and_CC side_NN scatter_NN
          properties_NNS of_IN lymphocytes_NNS were_VBD collected_VBN on_IN a_DT FACScan_NNP
          flow_NN cytometer_NN and_CC analyzed_VBD using_VBG CellQuest_NNP ®_NN software_NN
          (_( Becton_NNP Dickinson_NNP ;_: San_NNP Diego_NNP ,_, CA_NNP )_) ._.
        
        
          Primary_JJ and_CC secondary_JJ cell_NN cultures_NNS
          CD_NNP 4_CD +_NN T_NN cells_NNS were_VBD isolated_VBN from_IN spleen_NN and_CC lymph_NN nodes_NNS
          from_IN DO_NNP 11_CD ._. 10_CD TCR_NNP ×_NN hCARΔcyt_NN double_JJ transgenic_JJ mice_NNS by_IN
          positive_JJ sorting_VBG using_VBG anti-_NN CD_NNP 4_CD magnetic_JJ beads_NNS (_( Dynal_NNP AS_NNP ,_,
          Oslo_NNP ,_, Norway_NNP )_) ._. Greater_NNP than_IN 95_CD %_NN of_IN the_DT resulting_VBG cells_NNS
          were_VBD CD_NNP 4_CD positive_JJ and_CC were_VBD plated_JJ at_IN a_DT ratio_NN of_IN 1_CD :_: 5_CD with_IN
          irradiated_JJ BALB_NNP /_NN c_SYM splenocytes_NNS and_CC 5_CD μg_NN /_NN ml_NN ovalbumin_NN
          peptide_NN 323_CD -_: 339_CD ._. The_DT addition_NN of_IN 50_CD U_NNP /_NN ml_NN IL-_NNP 12_CD and_CC 10_CD
          μg_NN /_NN ml_NN anti-_NN IL-_NNP 4_CD was_VBD used_VBN to_TO generate_VB cells_NNS with_IN a_DT Th_NNP 1_CD
          phenotype_NN ,_, while_IN 1000_CD U_NNP /_NN ml_NN IL-_NNP 4_CD and_CC 10_CD μg_NN /_NN ml_NN anti-_NN IL-_NNP 12_CD
          was_VBD used_VBN to_TO generate_VB cells_NNS with_IN a_DT Th_NNP 2_CD phenotype_NN [_NN 29_CD ]_NN ._.
          After_IN the_DT initial_JJ isolation_NN of_IN the_DT naïve_NN CD_NNP 4_CD +_NN T_NN cells_NNS ,_,
          cultures_NNS were_VBD treated_VBN with_IN the_DT above_JJ cytokine_NN /_NN antibody_NN
          cocktail_NN weekly_JJ for_IN three_CD consecutive_JJ weeks_NNS to_TO ensure_VB
          complete_JJ polarization_NN ._.
        
        
          Adenoviral_NNP transduction_NN
          For_IN adenoviral_NN transduction_NN ,_, lymph_NN nodes_NNS and_CC spleen_NN
          cells_NNS were_VBD isolated_VBN ,_, treated_VBN with_IN ACK_NNP lysing_VBG buffer_NN for_IN 3_CD
          min_NN and_CC washed_VBN in_IN DMEM_NNP /_NN 10_CD mM_NN HEPES_NNP (_( pH_NN 7_CD ._. 2_LS )_) ._. Cells_NNP (_( 50_CD ×_NN
          10_CD 6_CD /_NN ml_NN )_) were_VBD incubated_JJ with_IN adenovirus_JJ at_IN a_DT multiplicity_NN
          of_IN infection_NN (_( MOI_NNP )_) of_IN 10_CD in_IN DMEM_NNP /_NN 10_CD mM_NN HEPES_NNP at_IN 37_CD °_NN C_NNP
          under_IN 5_CD %_NN CO_NNP 
          2_CD for_IN 30_CD min_NN with_IN gentle_JJ mixing_VBG every_DT
          10_CD min_NN ._. The_DT cells_NNS were_VBD then_RB washed_VBN with_IN PBS_NNP and_CC cultured_JJ
          in_IN RP_NNP 10_CD (_( RPMI_NNP 1640_CD (_( GIBCO_NNP /_NN BRL_NNP )_) /_NN 10_CD %_NN FBS_NNP (_( HyClone_NNP )_) /_NN 0_CD ._. 1_LS mM_NN
          2_CD -_: mercaptoethanol_NN /_NN 1_CD %_NN penicillin-streptomycin_JJ )_) at_IN 37_CD °_NN C_NNP /_NN 5_CD %_NN
          CO_NNP 
          2_CD until_IN analysis_NN ._. For_IN some_DT
          experiments_NNS ,_, the_DT transduced_JJ cells_NNS were_VBD then_RB activated_VBN
          with_IN 5_CD μM_NN ionomycin_NN and_CC 50_CD ng_NN /_NN ml_NN PMA_NNP for_IN 4_CD h_NN or_CC
          stimulated_VBN for_IN 18_CD h_NN by_IN immobilized_JJ anti-_NN CD_NNP 3_CD (_( pre-coated_JJ
          at_IN 10_CD μg_NN /_NN ml_NN in_IN PBS_NNP )_) or_CC 5_CD μg_NN /_NN ml_NN OVA_NNP peptide_NN with_IN
          antigen-presenting_JJ cells_NNS before_IN analysis_NN ._.
        
        
          Cytokines_NNP and_CC proliferation_NN assays_NNS
          CD_NNP 4_CD +_NN T_NN cells_NNS from_IN DO_NNP 11_CD ._. 10_CD TCR_NNP ×_NN hCARΔcyt_NN double_JJ
          transgenic_JJ mice_NNS (_( DO_NNP 11_CD ._. hCARΔcyt_NN )_) were_VBD isolated_VBN and_CC
          transduced_JJ as_IN described_VBN above_IN ._. After_IN 24_CD h_NN ,_, the_DT GFP_NNP
          positive_JJ and_CC GFP_NNP negative_JJ fractions_NNS of_IN the_DT transduced_JJ
          lymphocytes_NNS were_VBD sorted_VBN using_VBG a_DT Becton_NNP Dickinson_NNP
          FACSvantage_NNP and_CC cultured_JJ under_IN Th_NNP 1_CD or_CC Th_NNP 2_CD polarizing_VBG
          conditions_NNS as_IN described_VBN above_IN ._. For_IN cytokines_NNS assays_NNS ,_, 1_CD ×_NN
          10_CD 6_CD transduced_JJ cells_NNS were_VBD incubated_JJ on_IN anti-_NN CD_NNP 3_CD coated_JJ
          plates_NNS for_IN 72_CD h_NN at_IN 37_CD °_NN C_NNP /_NN 5_CD %_NN CO_NNP 
          2_CD ._. Culture_NNP supernatants_NNS were_VBD then_RB
          harvested_VBN and_CC an_DT ELISA_NNP assay_NN was_VBD performed_VBN to_TO measure_VB the_DT
          production_NN of_IN IL-_NNP 4_CD ,_, IL-_NNP 10_CD and_CC IFN-γ_NNP as_RB previously_RB
          described_VBD [_NN 30_CD ]_NN ._. To_TO assay_NN proliferation_NN ,_, the_DT transduced_JJ
          cells_NNS were_VBD plated_JJ in_IN duplicate_VB in_IN microtiter_NN plates_NNS (_( 5_CD ×_NN
          10_CD 5_CD /_NN well_RB )_) at_IN a_DT ratio_NN of_IN 1_CD :_: 5_CD with_IN irradiated_JJ BALB_NNP /_NN c_SYM
          splenocytes_NNS and_CC the_DT indicated_VBD doses_NNS of_IN OVA_NNP peptide_NN at_IN
          37_CD °_NN C_NNP /_NN 5_CD %_NN CO_NNP 
          2_CD ._. After_IN 72_CD h_NN ,_, 50_CD μCi_NN /_NN ml_NN [_NN
          3_CD H_NNP ]_NN thymidine_NN (_( Amersham_NNP ,_, Piscataway_NNP ,_, NJ_NNP )_) was_VBD added_VBN to_TO the_DT
          well_NN ._. Cells_NNP were_VBD further_JJ incubated_JJ for_IN 24_CD h_NN and_CC
          harvested_VBN ._. The_DT incorporation_NN of_IN [_NN 3_CD H_NNP ]_NN thymidine_NN was_VBD
          measured_VBN using_VBG a_DT LKB-Wallac_NNP (_( Gaithersburg_NNP ,_, MD_NNP )_)
          scintillation_NN counter_NN ._.
        
        
          Adoptive_NNP transfers_NNS
          CD_NNP 4_CD +_NN T_NN cells_NNS from_IN hCARΔcyt_NN transgenic_JJ mice_NNS were_VBD
          isolated_VBN and_CC transduced_JJ as_IN described_VBN above_IN ._. After_IN 24_CD h_NN in_IN
          culture_NN ,_, 5_CD ×_NN 10_CD 6_CD cells_NNS were_VBD washed_VBN in_IN DMEM_NNP ,_, resuspended_JJ
          in_IN 100_CD μl_NN of_IN DMEM_NNP and_CC injected_VBN in_IN the_DT tail_NN vein_NN of_IN 6_CD
          weeks_NNS old_JJ BALB_NNP /_NN c_SYM mice_NNS ._. The_DT mice_NNS were_VBD sacrificed_JJ after_IN 48_CD
          h_NN and_CC the_DT inguinal_NN ,_, axillary_JJ ,_, submandibular_NN and_CC
          mesenteric_JJ lymph_NN nodes_NNS ,_, the_DT spleen_NN and_CC the_DT Peyer_NNP 's_POS
          patches_NNS were_VBD isolated_VBN ._. Half_NN of_IN the_DT spleen_NN and_CC lymph_NN nodes_NNS
          were_VBD used_VBN for_IN flow_NN cytometric_JJ analysis_NN ._. The_DT remaining_VBG
          tissues_NNS were_VBD fixed_VBN for_IN 18_CD h_NN in_IN 4_CD %_NN formalin_NN in_IN PBS_NNP ,_, then_RB
          washed_VBN in_IN PBS_NNP and_CC frozen_VBN embedded_VBN in_IN OCT_NNP (_( Sakura_NNP Finetek_NNP ,_,
          Torrance_NNP ,_, CA_NNP )_) ._. Frozen_NNP sections_NNS of_IN the_DT spleen_NN ,_, lymph_NN nodes_NNS
          and_CC Peyer_NNP 's_POS patches_NNS were_VBD incubated_JJ with_IN 10_CD %_NN normal_JJ horse_NN
          serum_NN in_IN PBS_NNP ,_, counterstained_JJ with_IN biotin-labeled_JJ B_NNP 220_CD
          antibody_NN followed_VBN by_IN PE-labeled_NNP streptavidin_NN ,_, analyzed_VBD
          using_VBG a_DT Nikon_NNP E_NNP 800_CD fluorescent_NN microscope_NN with_IN a_DT SPOT_NNP
          imaging_NN system_NN (_( Diagnostic_NNP instruments_NNS ,_, Sterling_NNP Heights_NNP ,_,
          MI_NNP )_) and_CC counted_VBN as_RB previously_RB described_VBD [_NN 28_CD ]_NN ._.
        
        
          Statistical_NNP analyses_NNS
          Data_NNS from_IN experimental_JJ and_CC control_NN groups_NNS were_VBD
          evaluated_VBN by_IN the_DT Student_NNP t-test_JJ ._. Differences_NNS were_VBD
          considered_VBN significant_JJ when_WRB p_NN <_NN 0_CD ._. 05_CD ._.
        
      
      
        List_NN of_IN abbreviations_NNS
        Ad_NNP Adenovirus_NNP
        hCAR_NN human_JJ coxsackie_NN /_NN adenovirus_JJ receptor_NN
        MFI_NNP mean_VB fluorescence_NN intensity_NN
        MOI_NNP multiplicity_NN of_IN infection_NN
        OVA_NNP ovalbumin_NN
        PEV_NNP positional_JJ effect_NN variegation_NN
        Tg_NNP transgenic_JJ
      
      
        Authors_NNP '_'' contributions_NNS
        V_NNP ._. H_NNP ._. carried_VBD out_RP the_DT characterization_NN of_IN the_DT transgenic_JJ
        mice_NNS ,_, the_DT analysis_NN of_IN the_DT virally_RB transduced_JJ cells_NNS (_( flow_NN
        cytometric_JJ analysis_NN ,_, cytokine_NN and_CC proliferation_NN assays_NNS ,_,
        adoptive_JJ transfers_NNS )_) and_CC drafted_VBD the_DT manuscript_NN ._. R_NN ._. D_NNP ._. -_: H_NNP ._.
        conceived_VBD and_CC carried_VBD out_RP the_DT generation_NN of_IN the_DT transgenic_JJ
        mice_NNS (_( construct_VB ,_, sequencing_VBG )_) ,_, the_DT primary_JJ and_CC secondary_JJ
        cell_NN cultures_NNS (_( production_NN of_IN Th_NNP lines_NNS )_) and_CC corrected_VBD the_DT
        manuscript_NN ._. J_NNP ._. O_NNP ._. carried_VBD out_RP the_DT breeding_NN of_IN the_DT transgenic_JJ
        mice_NNS and_CC their_PRP$ genotyping_VBG ._. R_NN ._. J_NNP ._. M_NNP ._. participated_VBD in_IN the_DT
        design_NN of_IN the_DT study_NN and_CC corrected_VBD the_DT manuscript_NN ._. C_NNP ._. T_NN ._. W_NNP ._.
        conceived_VBD the_DT study_NN ,_, performed_VBD the_DT microscopic_JJ and_CC
        statistical_JJ analysis_NN of_IN the_DT transferred_VBN cells_NNS and_CC finalized_VBD
        the_DT manuscript_NN ._.
      
    
  
